Quotient, which sells diagnostic tests for blood grouping and serological disease screening, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The Midlothian, United Kingdom-based company, which was founded in 2007 and booked $19 million in sales for the 12 months ended December 31, 2013, plans to list on the NASDAQ under the symbol QTNT. Quotient initially filed confidentially on January 22, 2014. UBS Investment Bank, Baird and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
